PH-IPF Patients Treated with iNOpulse Could Benefit from Actigraphy

According to a Phase 2b clinical test findings, actigraphy is a highly useful device to identify meaningful clinical alteration in individuals suffering from pulmonary hypertension (PH) linked to interstitial lung disease (PH-ILD) when treated with INOpulse, a product created by Bellerophon Therapeutics. PH-ILD stands for PH patients suffering from idiopathic pulmonary fibrosis (PH-IPF).

The medical device actigraphy can be worn by an individual to track motor activity. The wearable equipment is used as a key destination in clinical testing to monitor a wide range of cardiopulmonary conditions, such as chronic obstructive pulmonary disorder (COPD).

The moveable pulsing device INOpulse offers nitric oxide (iNO) being inhaled by individuals by regulating its dosage in accordance with how the individuals breathe. Nitric oxide when inhaled, relaxes the muscle cells present in the blood vessels, and keeps the heart and lung healthy, which are the two main characteristics of PH.

The continuing iNO-PF Phase 2b trial continue to test the risks and efficiency of iNO based treatment in pulmonary fibrosis patients. The study has tested over 40 participants yet. The study respondents have been given either iNO or placebo, which includes a seven days run-in time period and a forty two days-long treatment. Actigraphy is being used in the trial to study the clinically important parameters in patients receiving iNOpulse treatment.

As per the recent findings PH-IPF respondents given INOpulse treatment showcased 8% rise in activity in comparison to the participants who were treated with placebo and experienced a decline of over 25% in activity.

Furthermore, individuals are also looking for diagnostic services for precise treatments of sleep related problems, which is also driving the demand for actigraphy sensor and PSG devices in the healthcare industry. Besides, the constant and advanced research on sleep disorder management to find out highly efficient medicine and treatments for fatal sleep disorders, continue to boost the applications and adoption of actigraphy sensor and PSG devices.

You might like


About the Author: Shambhu Nath Jha

Mr. Shambhu Nath Jha is a seasoned consultant and researcher. His research papers have been published in reputed websites and trade journals. His interests include philosophy and history.

Leave a Reply

Your email address will not be published. Required fields are marked *